In this study, we show that RRM2 expression is strongly correlated with malignant proliferation in patients with AML and that MB is a potent inhibitor of RNR enzymatic activity by targeting the RRM2 protein, thereby possessing significant anti-leukaemia efficacy in vitro and in vivo. This evidence concerns the gene RRM2 and acute myeloid leukemia.